WO2001066117A1 - Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor - Google Patents
Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor Download PDFInfo
- Publication number
- WO2001066117A1 WO2001066117A1 PCT/GB2001/001047 GB0101047W WO0166117A1 WO 2001066117 A1 WO2001066117 A1 WO 2001066117A1 GB 0101047 W GB0101047 W GB 0101047W WO 0166117 A1 WO0166117 A1 WO 0166117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogue
- derivative
- use according
- metronidazole
- hydrogen pump
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Definitions
- the present invention relates to the treatment of skin 5 conditions such as rosacea and similar inflammatory dermatoses, and m particular to the treatment of certain kinds of rosacea, and also perioral papular and pustular acne, and other papulopustular dermatoses.
- Rosacea is a chronic inflammatory disease which affects the face. It is characterised by episodic flushing, erythema, and telangiectasia affecting the cheeks, chin, forehead, and nose. It may be further complicated by inflammatory swelling, papules and pustules.
- H. Pylori Gram-negative bacterium Helicobacter pylori
- rosacea and similar inflammatory skin dermatoses can be effectively treated by administering to a patient a treatment regime comprising I) erythromycm, clarithromycm or an analogue or derivative thereof, n) metronidazole or an analogue or derivative thereof, and m) a gastrointestinal hydrogen pump inhibitor, such as omeprazole or an analogue or derivative thereof.
- the three drugs may be formulated for simultaneous, separate or sequential use.
- the triple drug combination according to the present invention functions in achieving the desired results.
- One possibility is that there may be a causal relationship between the dermatoses to be treated and H. pylori , such that eradication of H. pylori may lead to resolution of these dermatoses.
- Another possibility is that as, certain instances, the presence of H. pylori has been found m pustules on the skin, the triple drug combination may act directly to eradicate that external form of H. pylori .
- triple drug combination works m another manner, such that any apparent relationship between its use m the present invention and H .pylori may simply be coincidental, such that further study will be necessary elucidate its precise mode of action Description of the Invention
- the preferred treatment regime comprises erythromycm or clarithromycm, metronidazole and omeprazole, and the most preferred treatment regime comprises clarithromycm, metronidazole and omeprazole.
- analogues or derivatives of any of these drugs may be used provided that their combined administration achieves the desired result.
- another similar-acting macrolide antibiotic to erythromycm or clarithromycm may be used, for instance azithromycm or dirithromyc .
- lanzoprazole or any other drug which acts to inhibits a gastrointestinal hydrogen pump may be used instead of omeprazole.
- the three drugs may be useful which have a similar or equivalent pharmacological mode of action to the drugs named above.
- Pharmaceutically- acceptable salt forms of the drugs may also be used.
- Treatment may be by administration of the three drugs by any suitable means. Conveniently, however, the three drugs will be administered by one or a combination of oral administration, topical application to a patient's skin, or parenteral administration, e.g. intravenous, intramuscular or subcutaneous administration. For instance, one or more of the three drugs may be formulated for administration by a different route to the other drug(s) . Typically, it is desirable to administer omeprazole or an analogue thereof orally, but the other drugs may be formulated for oral, topical or parenteral administration, or any combination thereof. For instance, it may be preferred to administer omeprazole orally and the other two drugs topically, optionally as a combined topical formulation.
- the triple drug combination may take the form of separate pills containing each of the separate drugs, for simultaneous, separate or sequential administration.
- the three drugs will be combined into a single dosage form, preferably a tablet, capsule or linctus, for patient convenience.
- the drugs are incorporated into a suitable pharmaceutically-acceptable carrier.
- suitable pharmaceutically-acceptable carrier Such formulations have not been disclosed in the prior art, and constitute further aspects of the claimed invention.
- the relative proportions of the three drugs necessary for effective treatment may vary depending on the route of administration, and the particular patient to be treated.
- a patient will receive 200 to 600 mg, preferably 300 to 500 mg of erythromycin, clarithromycin or an analogue thereof, 200 to 500 mg, preferably 300 to 500 mg, metronidazole, and 10 to 100 mg, preferably 20 to 60 mg, omeprazole, on a daily basis.
- a particularly preferred treatment regime comprises about 250 mg erythromycin, clarithromycin or an analogue thereof, about 400 mg metronidazole and about 20 mg omeprazole.
- Treatment periods vary from patient to patient, from one week to a number of years .
- a score of one is given if less than half the area involved is affected by that parameter, and a score of two if half or more of the area is affected.
- the scores for the different parameters in the different facial areas are added together to give a total score for the patient.
- Each patient was subjected to clinical photography, and then treated with an oral dosage of 20 mg omeprazole, 400 mg metronidazole, and 250 mg clarithromycin for one week.
- Disease severity scoring and clinical photography were repeated at the end of weeks 6, 12, 18, and 24, and fourteen patients were followed for a period of 52 weeks.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU37628/01A AU3762801A (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
CA002413923A CA2413923A1 (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
EP01910045A EP1263445A1 (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00301951.0 | 2000-03-09 | ||
EP00301951A EP1133987A1 (en) | 2000-03-09 | 2000-03-09 | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
US18896100P | 2000-03-10 | 2000-03-10 | |
US60/188,961 | 2000-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001066117A1 true WO2001066117A1 (en) | 2001-09-13 |
Family
ID=26073033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/001047 WO2001066117A1 (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1263445A1 (en) |
AU (1) | AU3762801A (en) |
CA (1) | CA2413923A1 (en) |
WO (1) | WO2001066117A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049716A1 (en) * | 2001-12-13 | 2003-06-19 | Ranbaxy Laboratories Limited | Stable topical formulation of clarithromycin |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472225A2 (en) * | 1985-12-11 | 1992-02-26 | L V M H Recherche | Hydrated lammelar lipidic phases or liposomes containing tretinoid |
WO1993021920A1 (en) * | 1992-04-24 | 1993-11-11 | Astra Aktiebolag | Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
WO1995018612A1 (en) * | 1994-01-05 | 1995-07-13 | Aktiebolaget Astra | A method for treatment of psoriasis, by omeprazole or related compounds |
WO1996001622A1 (en) * | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
WO1996024375A1 (en) * | 1995-02-06 | 1996-08-15 | Astra Aktiebolag | New oral pharmaceutical dosage form |
JPH10158172A (en) * | 1996-11-29 | 1998-06-16 | Takeshi Azuma | Therapeutic agent for hepatic encephalopathy or preventing agent for hepatic encephalopathy |
WO1999007361A1 (en) * | 1997-08-05 | 1999-02-18 | Millennium Pharmaceuticals, Inc. | Methods for controlling gram negative bacteria in mammals |
WO1999024036A1 (en) * | 1997-11-07 | 1999-05-20 | Aberdeen University | Skin penetration enhancing components |
-
2001
- 2001-03-09 AU AU37628/01A patent/AU3762801A/en not_active Abandoned
- 2001-03-09 EP EP01910045A patent/EP1263445A1/en not_active Withdrawn
- 2001-03-09 WO PCT/GB2001/001047 patent/WO2001066117A1/en not_active Application Discontinuation
- 2001-03-09 CA CA002413923A patent/CA2413923A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472225A2 (en) * | 1985-12-11 | 1992-02-26 | L V M H Recherche | Hydrated lammelar lipidic phases or liposomes containing tretinoid |
JPH09110669A (en) * | 1985-12-11 | 1997-04-28 | Lvmh Rech | Composition for skin disease or for cosmetics |
WO1993021920A1 (en) * | 1992-04-24 | 1993-11-11 | Astra Aktiebolag | Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
WO1995018612A1 (en) * | 1994-01-05 | 1995-07-13 | Aktiebolaget Astra | A method for treatment of psoriasis, by omeprazole or related compounds |
WO1996001622A1 (en) * | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
WO1996024375A1 (en) * | 1995-02-06 | 1996-08-15 | Astra Aktiebolag | New oral pharmaceutical dosage form |
JPH10158172A (en) * | 1996-11-29 | 1998-06-16 | Takeshi Azuma | Therapeutic agent for hepatic encephalopathy or preventing agent for hepatic encephalopathy |
WO1999007361A1 (en) * | 1997-08-05 | 1999-02-18 | Millennium Pharmaceuticals, Inc. | Methods for controlling gram negative bacteria in mammals |
WO1999024036A1 (en) * | 1997-11-07 | 1999-05-20 | Aberdeen University | Skin penetration enhancing components |
Non-Patent Citations (5)
Title |
---|
ALDER, J. D. ET AL: "Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies", AM. J. GASTROENTEROL. (1996), 91(11), 2347-2354, XP000961369 * |
DATABASE WPI Week 199834, Derwent World Patents Index; AN 1998-393392, XP002152008 * |
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 11 30 September 1998 (1998-09-30) * |
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31) * |
XIA, HARRY HUA-XIANG ET AL: "Prospects for improved therapy for Helicobacter pylori infectio", EXPERT OPIN. INVEST. DRUGS (1996), 5(8), 959-976, XP000961342 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049716A1 (en) * | 2001-12-13 | 2003-06-19 | Ranbaxy Laboratories Limited | Stable topical formulation of clarithromycin |
Also Published As
Publication number | Publication date |
---|---|
AU3762801A (en) | 2001-09-17 |
EP1263445A1 (en) | 2002-12-11 |
CA2413923A1 (en) | 2001-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1363600B1 (en) | Liquid formulations for the prevention and treatment of mucosal diseases and disorders | |
Mehrabi et al. | Therapeutic agents in perioperative third molar surgical procedures | |
US20180264021A1 (en) | Treatment of papulopustular rosacea with ivermectin | |
ES2389539T3 (en) | Methods and compositions for the treatment of asthma | |
CN105362286A (en) | Otic compositions for the treatment of infections of the internal and external ear in mammals | |
CA2822320A1 (en) | Composition for the treatment of skin conditions | |
Schaller et al. | State of the art: systemic rosacea management | |
US9125927B2 (en) | Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea | |
US20210128548A1 (en) | External preparation comprising pyridonecarboxylic acid derivative | |
US20090163455A1 (en) | Avermectin/hydrocortisone compositions for treating afflictions of the skin, e.g., rosacea | |
CN113274384B (en) | Application of oryzaol in preparation of medicine for preventing and treating ulcerative colitis and medicine thereof | |
KR20190100442A (en) | Composition and method for treating otitis | |
EP1263445A1 (en) | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor | |
EP1133987A1 (en) | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor | |
US20140288102A1 (en) | Prevention of recurrences of urethral strictures following conventional therapy | |
JP2002308764A (en) | Pharmaceutical composition for ophthalmic use | |
Vardas et al. | Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation | |
EP3251676A1 (en) | Enema for rectal application | |
EP1670464A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
US20090197956A1 (en) | Treatment of acute otitis media with xylitol and n-acetylcysteine | |
US6693100B1 (en) | Pharmaceutical compositions for treating psoriasis | |
EP3664786B1 (en) | Method for treating schnitzler's syndrome | |
KR20170099911A (en) | Injectable formulations of paracetamol | |
WO2022094685A1 (en) | Composition, pharmaceutical composition, use of a stable topical composition comprising a nanoemulsion and of at least one antileishmanial compound, and method for the treatment of cutaneous leishmaniasis | |
WO2023108074A1 (en) | Novel salvinorin compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001910045 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001910045 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2413923 Country of ref document: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001910045 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |